230 related articles for article (PubMed ID: 11340684)
1. Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study.
Nasr SZ; Kuhns LR; Brown RW; Hurwitz ME; Sanders GM; Strouse PJ
Pediatr Pulmonol; 2001 May; 31(5):377-82. PubMed ID: 11340684
[TBL] [Abstract][Full Text] [Related]
2. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis.
Robinson M; Hemming AL; Moriarty C; Eberl S; Bye PT
Pediatr Pulmonol; 2000 Jul; 30(1):16-24. PubMed ID: 10862158
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group.
Harms HK; Matouk E; Tournier G; von der Hardt H; Weller PH; Romano L; Heijerman HG; FitzGerald MX; Richard D; Strandvik B; Kolbe J; Kraemer R; Michalsen H
Pediatr Pulmonol; 1998 Sep; 26(3):155-61. PubMed ID: 9773909
[TBL] [Abstract][Full Text] [Related]
4. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
[TBL] [Abstract][Full Text] [Related]
5. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.
Shak S
Chest; 1995 Feb; 107(2 Suppl):65S-70S. PubMed ID: 7842816
[TBL] [Abstract][Full Text] [Related]
6. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations.
Wilmott RW; Amin RS; Colin AA; DeVault A; Dozor AJ; Eigen H; Johnson C; Lester LA; McCoy K; McKean LP; Moss R; Nash ML; Jue CP; Regelmann W; Stokes DC; Fuchs HJ
Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1914-7. PubMed ID: 8665055
[TBL] [Abstract][Full Text] [Related]
7. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
Laube BL; Auci RM; Shields DE; Christiansen DH; Lucas MK; Fuchs HJ; Rosenstein BJ
Am J Respir Crit Care Med; 1996 Feb; 153(2):752-60. PubMed ID: 8564129
[TBL] [Abstract][Full Text] [Related]
8. The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease.
Nasr SZ; Sakmar E; Christodoulou E; Eckhardt BP; Streetman DS; Strouse PJ
Pediatr Pulmonol; 2010 May; 45(5):440-9. PubMed ID: 20425851
[TBL] [Abstract][Full Text] [Related]
9. Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis.
Robinson TE; Goris ML; Zhu HJ; Chen X; Bhise P; Sheikh F; Moss RB
Chest; 2005 Oct; 128(4):2327-35. PubMed ID: 16236891
[TBL] [Abstract][Full Text] [Related]
10. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
McCoy K; Hamilton S; Johnson C
Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
[TBL] [Abstract][Full Text] [Related]
11. [Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement].
Hodson M
Arch Pediatr; 1995 Jul; 2(7):679-81. PubMed ID: 7663660
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment.
Shah PI; Bush A; Canny GJ; Colin AA; Fuchs HJ; Geddes DM; Johnson CA; Light MC; Scott SF; Tullis DE
Eur Respir J; 1995 Jun; 8(6):954-8. PubMed ID: 7589382
[TBL] [Abstract][Full Text] [Related]
13. Airway inflammation after treatment with aerosolized deoxyribonuclease in cystic fibrosis.
Henry RL; Gibson PG; Carty K; Cai Y; Francis JL
Pediatr Pulmonol; 1998 Aug; 26(2):97-100. PubMed ID: 9727759
[TBL] [Abstract][Full Text] [Related]
14. [Clinical development of rhDNase in the United States].
Eisenberg J
Arch Pediatr; 1995 Jul; 2(7):674-8. PubMed ID: 7663659
[TBL] [Abstract][Full Text] [Related]
15. Bronchoscopically administered recombinant human DNase for lobar atelectasis in cystic fibrosis.
Slattery DM; Waltz DA; Denham B; O'Mahony M; Greally P
Pediatr Pulmonol; 2001 May; 31(5):383-8. PubMed ID: 11340685
[TBL] [Abstract][Full Text] [Related]
16. High resolution computerized tomography of the chest and pulmonary function testing in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis patients.
Nasr SZ; Gordon D; Sakmar E; Yu X; Christodoulou E; Eckhardt BP; Strouse PJ
Pediatr Pulmonol; 2006 Dec; 41(12):1129-37. PubMed ID: 17068818
[TBL] [Abstract][Full Text] [Related]
17. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group.
O'Donnell AE; Barker AF; Ilowite JS; Fick RB
Chest; 1998 May; 113(5):1329-34. PubMed ID: 9596315
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum.
Griese M; App EM; Duroux A; Burkert A; Schams A
Pulm Pharmacol Ther; 1997; 10(1):21-7. PubMed ID: 9344829
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis.
Nasr SZ; Strouse PJ; Soskolne E; Maxvold NJ; Garver KA; Rubin BK; Moler FW
Chest; 2001 Jul; 120(1):203-8. PubMed ID: 11451839
[TBL] [Abstract][Full Text] [Related]
20. [New method of scoring lung changes using computed tomography in patients with cystic fibrosis].
Iwanowska B
Med Wieku Rozwoj; 2012; 16(4):290-302. PubMed ID: 23378408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]